-
Sector Analysis
Head and Neck Squamous Cell Carcinoma – Global Drug Forecast and Market Analysis to 2030
Head and neck squamous cell carcinoma (HNSCC) was the sixth most common cancer type by worldwide incidence in 2020. However, until recently, there had been limited research and development in HNSCC, resulting in a market with little competition and a stagnant pipeline. Historically, cytotoxic chemotherapies have made up the majority of the HNSCC market. There is currently little competition between targeted therapies in the HNSCC market, leaving an area of considerable opportunity for interested newcomers. Despite the approvals of PD-1...
-
Sector Analysis
HER2+ Breast Cancer – Global Drug Forecast and Market Analysis to 2030
GlobalData valued the 8MM HER-2 + breast cancer market at $10.4 billion in 2020 and expects the market to increase at a low compound annual growth rate (CAGR) of more than 1%. This growth will be driven by the anticipated launches of five pipeline agents, the expansion of several currently approved agents into earlier lines of therapy, and a collective increase in the diagnosed incident population across the 8MM. Growth will be substantially inhibited by generic and biosimilar erosion following...
-
Sector Analysis
Endometrial Cancer – Global Drug Forecast and Market Analysis to 2030
EC is a uterine malignancy which is often diagnosed in the early stages of the disease due to the common symptom of post-menopausal bleeding. Due to the early diagnosis rate, surgery is the upfront treatment option for patients and only patients with high-risk of relapse are considered for adjuvant therapy with chemotherapy or hormone therapy. The unmet needs associated with EC arise for patients that relapse the upfront therapy since there is a lack of treatments available for advanced and...
-
Sector Analysis
Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030
The global neuroendocrine tumors drug market was valued at $3.11 billion in 2020 and is projected to grow at a CAGR of more than 0.5% during the forecast period 2021-2030. The introduction of five new pipeline agents and label expansions or entry into new markets for currently approved agents are key drivers of this market growth. However, the market will largely stagnate during the forecast period due to patent expiries impacting most of the standard of care. The US was...
-
Sector Analysis
PharmaPoint: Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2023
Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will experience dramatic changes over the forecast period as patents expire and promising new therapies enter the market. A large share of the RCC market is currently dominated by a few large companies, but they will struggle to retain these shares as they are joined by new...
-
Sector Analysis
OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025
Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission,...
-
Sector Analysis
Hodgkin’s Lymphoma - Opportunity Analysis and Forecasts to 2029
HL is a rare hematological malignancy that arises from the lymphatic system. Although HL is a rare condition, it has a high cure rate due to the positive response to treatment which combines chemotherapy, targeted therapy, radiotherapy and stem cell transplant accordingly. The World Health Organization (WHO) classifies HL into two main types: classical HL (CHL) and nodular lymphocyte-predominant HL (NLPHL), which CHL accounts for 95% of cases. Historically, treatment of HL has been mostly reliant on chemotherapies, radiotherapy and...
-
Sector Analysis
Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029
Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses. The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX...
-
Sector Analysis
Hepatocellular Carcinoma – Opportunity Analysis and Forecasts to 2029
The hepatocellular carcinoma (HCC) market is expected to grow from $1.4bn in 2019 to $5.5bn in 2029 in the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 14.5%. The significant growth in the therapy market is driven by implementing new strategies such as developing combinations of therapies with different mechanism of actions, label expansion of marketed therapies for HCC into earlier lines of therapy, and label expansion of drugs approved in other indications into HCC. Mandana...
-
Sector Analysis
OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2024
The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.